Insider filing · ALMS

James B. Tananbaum bought $7.0M of Alumis (ALMS)

Executed Jan 8, disclosed Jan 13, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Jan 12), the stock returned +36.0% (delay-adjusted); from the execution session (Jan 8), +43.5%. Derived: entry at the session's open, exit at the close 20 sessions later.

JT James B. Tananbaum Director profile →

James B. Tananbaum (Director) filed 4 Form 4 reports in the trailing twelve months (4 purchases, 0 sales), most often in Alumis Inc. (ALMS). Across 4 priced purchase filings, the average 21-session return was +61.1% from execution and +48.9% from disclosure (delay-adjusted; derived). The largest single filing was $7.0M of ALMS (411,764 sh across 2 lots, as filed), executed Jan 8.

ALMS Alumis Inc. ALMS · Healthcare · 24 filings in 24 months ticker →

Healthcare · Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disor…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→